GlassScriptPhysician profile
Jaime G Oakley
NPI 1013966886
$3,807.29
in general payments reported to CMS, 2019-2025
39 companies · $766 in 2025
The $766 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $347 · 2021: $397 · 2022: $310 · 2023: $494 · 2024: $575 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,835.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.86 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.51 | 2019-2023 | |
| Novo Nordisk INC | $365.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $346.02 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $216.20 | 2019-2025 | |
| Allergan, INC. | $197.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $160.38 | 2020-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $154.12 | 2019-2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $100.06 | 2024-2025 | Voquezna |
| Welch Allyn | $99.98 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.32 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $71.91 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $53.56 | 2019 | |
| Exact Sciences Corporation | $51.79 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $46.13 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Oakley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.